Humana Inc. fell short of pleading standards in its racketeering lawsuit against Biogen Inc. over its allegedly fraudulent ...

Sage (SAGE) is reportedly suing Biogen (BIIB) over enforcement of a standstill agreement in the wake of an unsolicited ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...

GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

Of the 24 drugs, three approvals deviated from the others -- aducanumab; the synthetic hormone hydroxyprogesterone caproate ...

The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for ...

The OIG report points to gaps in documentation and decision-making transparency, particularly in the case of Aduhelm, where FDA records indicated only 13 meetings with Biogen, but congressional ...

Shares of Biogen Inc. BIIB shed 1.44% to $141.00 Wednesday, on what proved to be an all-around positive trading session for ...

Artbio, a clinical-stage radiopharmaceutical company, named Johnson & Johnson alum Margaret Yu as chief medical officer. Saisei Ventures tapped Dr. Sven Kili as partner. OSE Immunotherapeutics ...